BRG1 targeting STAT3/VEGFC signaling regulates lymphangiogenesis in colorectal cancer

Xu Zhu(Tongji Hospital), Jing Wang(Inserm), Jingqin Lan(Tongji Hospital), Meng Zhang(First Affiliated Hospital of Zhengzhou University), Junbo Hu(Tongji Hospital), Xianglin Yuan(Tongji Hospital), Linli Xu(University of Science and Technology of China), Li Sun(Atrium Health Wake Forest Baptist), Xuelai Luo(Tongji Hospital), Guihua Wang(Hengyang Academy of Agricultural Sciences), Jianping Gong(Fujian Medical University)
Oncotarget
April 27, 2016
10.18632/oncotarget.9038
Cited by 15

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
|Cancer Research|2018|672
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
|Cell|2019|601
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350